Given the genetic evidence demonstrated in our study, future clinical trials should assess the efficacy and safety of GLP‐1R agonists specifically for OSA treatment, including in non‐obese individuals and across diverse populations. The gene discussed is GLP1R; the disease is obstructive sleep apnea syndrome.